Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about the anticipation of results for a hair loss treatment study, specifically for GT20029, with expectations for the results to be released in the first quarter of 2024. No specific treatments were discussed.

Pyrilutamide phase 3 results showed little to no significant hair regrowth, but may be sufficient for maintaining current hair density. The user is unsure due to lack of recent discussions on pyrilutamide.

The conversation discusses the high prices of hair loss treatments, specifically cb-03-01 and KY19382. It also mentions the use of Minoxidil, finasteride, and RU58841.

The conversation discusses the potential market release of a hair loss treatment called GT20029 by Anageninc, with users expressing interest and discussing the importance of safety and effectiveness. Some users plan to contact Anageninc to show demand for the product.

A 21-year-old experiencing hair loss since age 16 is using 1mg dutasteride, 5mg minoxidil, and Nizoral, with occasional microneedling, but stopped microneedling due to scalp inflammation. They report some patchy regrowth, with stronger results at the front than the midsection.

Minoxidil, PRP, low-level light therapy, stem cell therapy, mesotherapy, Acell, and microneedling are discussed as treatments for thickening fine hairs in NW5 hair loss sufferers. A hair transplant may be necessary for significant improvement.

The user diagnosed with DUPA tried treatments like dutasteride, finasteride, RU58841, and minoxidil without success and is considering a hair system. They hope for a future cure, possibly with PP405, and others suggest options like scalp biopsy and SMP.

Genetic differences in hair follicles affect hair loss patterns. Treatments discussed include finasteride, dutasteride, minoxidil, and RU58841.

An 18/19-year-old male started balding at 16 and initially saw hair growth with minoxidil, but results diminished over time. He switched dermatologists and is now using a regimen of topical finasteride, minoxidil, vitamin D, and supplements, hoping for better results.

PP405 shows promise in hair regrowth, with 31% of participants experiencing over 20% increase in hair density after 8 weeks. Phase 3 trials are expected in 2026, with potential market availability by 2029-2031.

The conversation is about comparing the effectiveness of fluridil and clascoterone in preventing hair loss and inquiring about their use as standalone treatments. There is a question about the concentration of the fluridil brand for efficacy.

A 21-year-old male has been using dutasteride, minoxidil, ketoconazole shampoo, and microneedling for hair loss, with plans to increase minoxidil dosage. He is experiencing no side effects and is planning a trichoscopy to assess hair regrowth.

The conversation discusses Kintor's initiation of a new Phase 3 trial to assess the long-term safety of Pyrilutamide (KX-826) for hair loss, which will last 52 weeks. Specific treatments mentioned include Pyrilutamide.

Kintor Pharma has finished enrolling the first patient in a Phase III trial for KX-826, a treatment for androgenetic alopecia (AGA). One user has set a reminder to check back on the topic in a year.

User tried oral finasteride, topical finasteride, topical dutasteride, and RU58841 but experienced side effects. They discuss upcoming treatments like clascoterone, pyrilutamide, gt20029, and KY19382 as potential options.

Emerging hair loss treatments like PP405, a topical MPC inhibitor, show promise in activating stem cells for hair growth. The conversation seeks information on the development stages and accessibility of these treatments.

A 15-year-old is experiencing uneven hair loss, with one temple receding significantly. They are considering using finasteride, minoxidil, or dutasteride to slow hair loss before visiting a dermatologist, and may consider a hair transplant in the future.

PP405 is a potential hair loss treatment undergoing trials, with discussions on its effectiveness and comparison to existing treatments like finasteride and minoxidil. There is skepticism about its status as a cure, with hopes for future advancements in genetic treatments like CRISPR.

Pyrilutamide, a new drug being tested to combat hair loss that has been found to perform comparably or better than finasteride and dutasteride in the initial 6 months of treatment with minimal reported side effects.

Verteporfin shows promise in donor hair regeneration after 84 days. Combining Finasteride, Minoxidil, and Pyrilutamide with unlimited hair transplants is seen as a potential near-cure for hair loss.

Hair loss treatments, specifically about the effectiveness of RU58841 compared to Pyrilutamide. Molecular weights and side effects were discussed in terms of efficacy and cost-effectiveness.

User discusses potential hair loss treatment SCUBE3 and shares mixed opinions on its effectiveness. One user reports positive results after applying SCUBE3 following microneedling.

A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.

User shared 3-week progress using Pyrilutamide once a day for hair loss. Another user shared their 3-month progress with 0.25% concentration Pyrilutamide, experiencing rollback of 4 years in 3 months.

Koshine 826 (Pyrilutamide) is being used by several users to address hair loss, with mixed results on shedding and side effects. Some users report reduced shedding and no side effects, while others experience increased shedding and potential issues with libido and erectile dysfunction.

A 23-year-old male experienced nipple sensitivity after starting finasteride for hair loss and stopped using it due to concerns about gynecomastia. He is worried about the risk of developing gynecomastia if he resumes finasteride, especially with plans to increase muscle mass.

A 21-year-old female is experiencing rapid hair shedding and receding hairline despite trying various treatments like hydration, vitamins, and castor oil. Medical tests showed normal results, and she seeks advice as the hair loss continues.

A Silicon Valley-backed company aims to cure hair loss. Exciting advancements include mRNA therapies, gene editing, hair cloning, AR degraders, anti-androgens, cell-based rejuvenation, and AI-based drug discovery, with hopes for FDA approval of GT20029 within 10 years.

A user shared their successful hair loss treatment using 1.25mg finasteride daily, 2.5mm microneedling every 1-3 weeks, zinc pyrithione shampoo, occasional scalp massages, and 40% glycolic acid on temples. They reported significant progress over 21 months.

PP405 is moving to late-stage trials, showing potential for hair regrowth, with 31% of male patients experiencing a 20% increase in hair density. Veradermics is developing an oral minoxidil version, and there is interest in combining treatments for better results.